Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Minerals processing company Zeotech (ZEO) has secured $3.7 million through a placement for its pilot plant program
  • The company issued over 52 million shares at 7 cents each, an 11.4 per cent discount to the last traded price
  • Funds will be used to upgrade the current single-feed kaolin pilot plant program to a dual-feed pilot, advance the existing carbon capture research program and further expand research opportunities
  • On the market today, Zeotech is down 1.28 per cent and is trading at 7.7 cents per share

Zeotech (ZEO) has secured $3.7 million through a placement for its pilot plant program.

The minerals processing company issued over 52 million shares at 7 cents each, an 11.4 per cent discount to the last traded price.

Funds will be used to upgrade the current single-feed kaolin pilot plant program to a dual-feed pilot, advance the existing carbon-capture research program and further expand research opportunities.

"The company is delighted by the overwhelming support for the capital raising, highlighting investor and shareholder confidence in Zeotech’s future growth and enabling accelerated execution of its strategy," Managing Director Peter Zardo said.

"Investment in the upgrade to a dual-feed pilot plant program, to include lithium process residue and further expansion of carbon capture studies, is an indication of early commercial interest in the company’s cleantech solutions and the future potential they present in creating shareholder value," he added.

The pilot plant will allow Zeotech to produce customer-scale samples of suitable
quantities of synthetic zeolite product for potential end-users.

Earlier this year, Zeotech transferred a key intellectual property assignment from its development partner, the University of Queensland.

The intellectual property relates to a patent-pending mineral processing technology for the synthetic manufacture of zeolites, developed in partnership with the university.

On the market today, Zeotech is down 1.28 per cent and is trading at 7.7 cents per share at 12:26 pm AEST.

ZEO by the numbers
More From The Market Herald
BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch - The Market Herald

" BARD1 Life Sciences (ASX:BD1) updates the market on Q4

BARD1 Life Sciences (BD1) has reported advances across its sales, business development and commercialisation activities over the June quarter.
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) has a progressive fourth quarter

Incannex Healthcare (IHL) has spent the fourth quarter progressing its cannabinoid pharmaceutical products and psychedelic medicine therapies.
Prescient Therapeutics (PTX) - CEO & Managing Director, Steven Yatomi Clarke - The Market Herald

" Prescient Therapeutics (ASX:PTX) advances clinical studies in June quarter

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter.
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu - The Market Herald

" Mesoblast (ASX:MSB) trades lower following June quarterly report

Drug developer Mesoblast (MSB) is trading red following the release of its latest quarterly financial report.